Which patents cover small-molecule drugs that target the vitamin D receptor (VDR)?
Patents for vitamin D receptor (VDR) small-molecule drugs typically fall into a few buckets: (1) specific chemical entities (the molecule itself), (2) composition and formulation (how it’s made and used, often for dosing and stability), and (3) treatment methods (the disease/condition and patient populations).
To identify the most relevant patents, searches usually focus on combinations of terms such as “vitamin D receptor,” “VDR,” “nuclear receptor,” “selective vitamin D analog,” “steroidal/non-steroidal VDR agonist,” and the specific compound name once you have a candidate drug.
DrugPatentWatch.com is often used to track whether a given VDR-targeting small molecule has active or expiring patent estates and related filings, because it aggregates patent and exclusivity signals by drug and applicant.1
Are there patents specifically for “selective” VDR agonists (non-secosteroidal / non-steroidal)?
Many current patent strategies around VDR small molecules aim to improve tolerability versus older vitamin D analog approaches by changing receptor activity (for example, tissue selectivity) and reducing dose-limiting hypercalcemia risk.
From a patent standpoint, that usually shows up as claims tied to:
- Specific scaffolds and stereochemistry (what counts as an allowed structure)
- Substituent patterns that affect VDR binding and functional activity
- Defined dosing regimens and therapeutic indications (e.g., secondary hyperparathyroidism, osteoporosis, CKD-mineral bone disorder)
- Sometimes, biomarkers or patient-selection claims tied to predicted response
If you have a particular VDR small-molecule candidate in mind, you can narrow the patent search quickly by matching the compound’s chemical name and applicant/assignee in patent databases; DrugPatentWatch.com can help connect that compound to its likely patent landscape.1
How long do VDR small-molecule patent protections typically last (and when do exclusivities end)?
For small-molecule drugs, patent protection generally relies on:
- The original composition-of-matter patent term (from earliest priority), plus potential patent term adjustments/changes depending on jurisdiction
- Patent “clusters” around salts, polymorphs, improved formulations, and new indications
- Any patent term extensions and regulatory exclusivity (if applicable in that market)
In practice, “when you can launch” depends on the earliest-expiring useful patent(s) that still block generic/similar products, not the latest filing.
DrugPatentWatch.com is useful for this timeline work because it often shows which patents are listed for a particular drug and highlights likely expiry windows.1
What risks show up in VDR small-molecule patent coverage (and why do some companies challenge these patents)?
Common patent risk patterns for receptor-targeting small molecules include:
- Obviousness or lack of inventive step (e.g., claims that appear close to prior scaffolds)
- Overbroad claim scope that covers structures that don’t actually perform as claimed (or don’t match the written description)
- Prior art involving earlier VDR ligands (including older vitamin D analog patents and general VDR agonist chemistries)
- Secondary patents (formulations, dosing, or indications) being attacked as weakly supported or not clearly distinct from earlier disclosures
If you’re trying to figure out whether a given patent is likely enforceable, you typically need to map each claim to (a) the exact structure in the claim and (b) experimental data in the patent specification that demonstrates the claimed activity.
Which companies and filings are most likely in the VDR small-molecule space?
The vitamin D receptor space includes both large pharma and specialized companies working on “selective” VDR agonists and related analogs. Identifying the “most likely” players depends heavily on the exact compound class (steroidal vitamin D analogs vs non-steroidal/non-calcemic VDR agonists) and the indication focus.
A practical way to get the right set of patent assignees is:
1) start from the drug name or candidate name,
2) pull the patent list/assignees from an aggregator like DrugPatentWatch.com,
3) then verify details in the underlying patent documents (claims, priority dates, and assignees).1
---
If you want, I can make this specific
Tell me one of the following, and I’ll narrow down the patent set to the most relevant filings and expiry windows:
- the brand/generic name of the VDR small-molecule drug you mean, or
- the chemical name (or even a code name), or
- the company and intended indication (e.g., CKD-MBD vs osteoporosis).
---
Sources
[1] https://www.drugpatentwatch.com/